Cooper Andrew J M, Willis Jenna, Fuller Janice, Benecke Heike, Leighton-Scott James, Andersohn Frank, Kim Joseph, Maier Christoph, Knaggs Roger D
Mundipharma Research Ltd., Cambridge Science Park, Milton Road, Cambridge, CB4 0GW, UK.
Mundipharma Research GmbH & Co. KG, Höhenstraße 10, 65549, Limburg, Germany.
Pain Ther. 2017 Jun;6(1):73-84. doi: 10.1007/s40122-017-0070-9. Epub 2017 Apr 27.
The prevalence of prescription opioid use disorders in the US has increased markedly in parallel with increases in opioid prescribing. Whilst an increase in opioid prescribing has also occurred in the UK, it remains unknown if there have been concurrent increases in opioid use disorders. The aim of this study was to examine national trends in the prevalence and incidence of physician-diagnosed opioid use disorders in the UK.
In a retrospective electronic health care database analysis using data from the UK Clinical Practice Research Datalink (CPRD), we identified persons receiving a first opioid prescription between January 1, 2008 and December 31, 2012. Persons with an opioid use disorder were identified by Read codes assigned by patients' physicians within 6 months following an opioid prescription. We calculated prevalence and incidence rates by dividing the analysis population by the total number of patients exposed (prevalence) or the total patient-years of exposure (incidence) using the 'exact' Clopper-Pearson Binomial method.
Our analysis included 714,699 person-years of prescription opioid exposure. The 5-year period prevalence of opioid use disorders was 4.61 (95% CI 4.28-4.96) per 10,000 individuals, or 0.05%. The incidence rate of opioid use disorders was of 6.51 (95% CI 5.93-7.13) patients per 10,000 patient-years exposed. When examined by study year, there was no clear suggestion of a changing trend over time. When stratified by opioid drug, trends in the incidence rate during the study were either stable (i.e., codeine and tramadol), increasing (i.e., morphine) or decreasing (i.e., dihydrocodeine).
Our study demonstrates that despite the marked increase in overall opioid prescribing in the UK in the past decade, there has not been an increase in the incidence of physician-diagnosed opioid use disorders.
在美国,处方阿片类药物使用障碍的患病率随着阿片类药物处方量的增加而显著上升。虽然英国的阿片类药物处方量也有所增加,但尚不清楚阿片类药物使用障碍是否同时增加。本研究的目的是调查英国医生诊断的阿片类药物使用障碍的患病率和发病率的全国趋势。
在一项回顾性电子医疗数据库分析中,我们使用来自英国临床实践研究数据链(CPRD)的数据,确定了在2008年1月1日至2012年12月31日期间首次接受阿片类药物处方的人员。阿片类药物使用障碍患者是通过患者医生在阿片类药物处方后6个月内分配的Read编码来确定的。我们使用“精确”的Clopper-Pearson二项式方法,通过将分析人群除以暴露患者总数(患病率)或总暴露患者年数(发病率)来计算患病率和发病率。
我们的分析包括714,699人年的处方阿片类药物暴露。阿片类药物使用障碍的5年期间患病率为每10,000人中有4.61(95%CI 4.28 - 4.96),即0.05%。阿片类药物使用障碍的发病率为每10,000暴露患者年中有6.51(95%CI 5.93 - 7.13)例患者。按研究年份检查时,没有明显的随时间变化趋势。按阿片类药物分层时,研究期间发病率的趋势要么稳定(即可待因和曲马多)、上升(即吗啡)或下降(即二氢可待因)。
我们的研究表明,尽管在过去十年中英国阿片类药物的总体处方量显著增加,但医生诊断的阿片类药物使用障碍的发病率并未增加。